Table 2.
Pharmacodynamic parameters derived from the curves of inhibition of ADP- and collagen-induced platelet aggregation vs time obtained after oral administration for 7 days of sibrafiban (2 mg twice daily) or ticlopidine (250 mg twice daily)/aspirin (80 mg twice daily) alone or in combination.
| Treatment | |||
|---|---|---|---|
| Parameter | Sibrafiban (n = 12) | Ticlopidine+aspirin (n = 12) | Sibrafiban+ticlopidine+aspirin (n = 11) |
| ADP-induced platelet aggregation | |||
| AUE(0,12 h) (% inhibition h) | 503±206 | 660±119 | 833±158 |
| AUE(0,24 h) (% inhibition h) | 825±412 | 1252±263 | 1292±336 |
| Average inhibition over 12 h (%) | 42±17 | 55±10 | 69±13 |
| Emax (%) | 65±18 | 68±7.5 | 89±53 |
| tEmax (h) | 5.5±4.1 | 37±60 | 5.7±1.3 |
| Collagen-induced platelet aggregation | |||
| AUE(0,12 h) (% inhibition h) | 396±293 | 962±135 | 996±159 |
| AUE (0,24 h) (% inhibition h) | 677±521 | 1852±370 | 1594±430 |
| Average inhibition over 12 h (%) | 33±24 | 80±11 | 83±13 |
| Emax (%) | 63±33 | 90±9 | 100±0 |
| tEmax (h) | 10.3±9.6 | 7.5±5.3 | 3.6±2.6 |